関連する実験動画

Updated: Nov 17, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K

進行した前立腺がんに対する皮膚経由のエストロゲン

Charlene Mantia1, Atish D Choudhury1

  • 1Dana-Farber Cancer Institute, Boston, MA 02215, USA.

Lancet (London, England)
|February 14, 2021
PubMed
まとめ

No abstract available in PubMed .

さらに関連する動画

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.7K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

246

関連する実験動画

Last Updated: Nov 17, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.7K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

246

関連する概念動画

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

Circulating Tumor DNA as Emerging Predictive and Prognostic Biomarker in Prostate Cancer.

Cancers·2026

Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer.

NPJ precision oncology·2026

Radiation and Avelumab in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.

Clinical genitourinary cancer·2026

A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial.

Nature medicine·2026

ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial.

Lancet (London, England)·2026

Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

Lancet (London, England)·2026

Psoriasis.

Lancet (London, England)·2026

Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2026

Immune Pathways in Doxorubicin Cardiotoxicity: A Cardio-Immunology Perspective: JACC CardioOncology State-of-the-Art Review.

JACC. CardioOncology·2026

Curcumin protects SH-SY5Y cells against glutamate-induced excitotoxicity by maintaining genomic integrity and antioxidant balance.

Drug and chemical toxicology·2026

Carotid in-stent restenosis and re-restenosis treated with drug-eluting balloon dilation - case report and literature review.

Ideggyogyaszati szemle·2026

A Retrospective Comparison of Survival, Tumour Reduction and Relapse Outcomes Following Oclacitinib and CCNU Treatment in Dogs With Canine Epitheliotropic T-Cell Lymphoma.

Veterinary dermatology·2026

A Successful Multimodal Treatment for High-Grade Serous Ovarian Cancer with BRCA2 Heterozygous Deletion with Multiple Recurrences: A Case Report.

Case reports in oncology·2026

Navigating Shared Decision-Making in Non-Operative Management of Locally Advanced Rectal Cancer.

Clinics in colon and rectal surgery·2026
関連記事をすべて見る
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー
Jove
Visualize
お問い合わせ